Ian Haydock

Latest From Ian Haydock
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast version of Five Must-Know Things: a look a top executive compensation; BioMarin preps for Roctavian’s EU debut; Argenx eyes launch hat-trick for Vyvgart; is a biopharma M&A wave coming; and J&J’s Gorsky offers leadership lessons.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast version of Five Must-Know Things: Genmab confident in CD20xCD3 battle; Alzheimer’s disappointment for Roche; Japan speed bump for Shionogi’s oral COVID antiviral; pharma’s view of psychedelics; and a roundup of key BIO sessions.
Asia Deal Watch: invoX Builds Novel Pipeline Through $161m F-star Acquisition
F-star's novel bispecific technology attracts Sino Biopharma-affiliated acquisition, Shionogi agreement with GARDP brings antibiotic cefiderocol to 135 countries, deal with WinHealth covering Greater China expands Quoin’s licensing of Netherton syndrome candidate to 60 nations, Kyorin and CellGenTech team up in Fabry disease.
Shionogi Hit By Surprise Japan Road Bump For Oral COVID Drug
After months of speculation and anticipation, Shionogi’s once-daily oral antiviral for the treatment of COVID-19 has stumbled after receiving an unexpected preliminary decision on its emergency approval from an advisory committee in Japan.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast version of Five Must-Know Things: key takeaways from BIO; a new alopecia option in the US; how one small specialist company entered Japan; and the evolving BTK inhibitor landscape in multiple sclerosis.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast version of Five Must-Know Things: paradigm-shifting breast cancer and KRAS inhibitor results at ASCO; BMS’ targeted oncology acquisition; a snapshot of the multiple sclerosis market; and a look at Aduhelm one year later.